The invention generally relates to radiation therapy equipment and radiation treatment, and in particular to systems and methods for converting electronic portal imaging device (EPID) images to simulated absolute dose planes in a measurement phantom for supporting intensity modulated radio therapy (IMRT) dose quality assurance (QA).
There is a need for an accurate estimation of absolute dose within planes, by way of example in a phantom, based on an input of Mega-voltage (MV) EPID images. As described in U.S. Pat. Nos. 6,345,114 for Method and Apparatus for Calibration of Radiation Therapy Equipment and Verification of Radiation Therapy, and 6,839,404 for System and Method for Positioning an Electric Portal Imaging Device, EPIDs is well known. Advantages of the EPID include'online convenience, data resolution (small pixels), and data density. However, MV EPIDs are not dosimeters, as the interactions of photons leading to an EPID image are notably different than the interactions in water or tissue that lead to radiation dose. It is desirable to maintain the industry standard of measured dose-to-calculated dose to perform IMRT QA analysis. Therefore comparison of anything other than dose, such as comparing a measured image to a predicted image is an undesirable shift from comparing a measured dose plane to a calculated dose plane. Additionally, percent differences, distance to agreement (DTA), and gamma criteria used in IMRT QA are based on a dose-in-tissue/water rationale.
There is also a need for an independent and reliably robust analysis. Any QA solution that is built into a radiation delivery system is a “self check,” which results in a fundamental conflict of interest due to the lack of a 3rd party independence. By way of example, exposing potential errors via independent and rigorous QA is a high ranking goal of medical physics. Relying completely on one system for planning, delivery, and QA reduces the likelihood of catching errors due to shared components, internal biases, and conflicting objectives.
Typical EPID images have pixel values that do not have dose equivalent units, for example are not centi-Gray (cGy). As a result using raw EPID images generates comparisons that are quantitative but not dosimetric. In such a case, use of standard intensity modulated radiography quality assurance (IMRT QA) analysis tools (DTA and gamma especially) is questionable unless acceptance criteria are re-established for non-dosimetric images. Additionally, the EPID image is typically acquired in a different geometry than is typical for IMRT QA. In other words, it is acquired at a different source-to-detector distance and with different build-up characteristics.
By way of further example, EPID detectors exhibit a different response with respect to energy spectra and scatter radiation than do dosimeters providing dose in tissue/water. Further, EPID images have a point spread response that is different than a dose kernel superposition of dose at depth in tissue/water. Yet further, EPID images exhibit off-axis/wide field variations in response.
There is a need for EPID-to-Dose conversions that allow IMRT QA to remain dose-based. There is also a need to estimate an absolute dose delivered in standard IMRT QA conditions including factors such as tissue equivalent buildup, source-to-detector distance, dose to tissue, and the like.
The present invention provides a system and method for converting electronic portal imaging device (EPID) images to an absolute dose at a simulated absolute dose plane in a measurement phantom for supporting intensity modulated radio therapy (IMRT) dose quality assurance (QA) by projecting the EPID image geometrically as may be required, generating an output factor correction map specific to a radiation treatment beam, multiplying an EPID image by the output factor correction map for generating an output corrected EPID image, and convolving the output corrected EPID image with a redistribution kernel for generating a relative dose at a preselected dose plane. A wide field calibration map is then applied to the relative dose for generating an absolute dose at the preselected dose plane location.
One embodiment is herein referred to as EPIDose™ and provides an EPID-to-Dose conversion that allows IMRT QA to remain dose-based. EPIDose™ includes a physics modeling module that accounts for differences such as output factor variation and dose distribution kernels between EPID response and tissue dose. A user may configure a physics model for each linear accelerator (e.g. a Linac) energy level being used. The EPIDose™ physics modeling may incorporate baseline absolute dose measurements from a high resolution dose detector array, by way of example, to create a unique calibration for predicting an absolute dose. This EPIDose™ physics model fuels an EPIDose™ process, which when applied to a raw EPID image in the EPIDose™ process allows the image to be converted to a dose plane within seconds.
For one embodiment of the invention, and to satisfy a need for independent and robust analysis as above described, by opening EPIDose™ files in MapCHECK™ software for analysis, complete autonomy from the delivery system is achieved and a complete suite of analysis options is available. MapCHECK™ is a two dimensional detector array useful in providing a quick and precise verification of radiotherapy dose distributions. While other systems may be used, MapCHECK™ is herein presented by way of one example for use with embodiments of the invention and is a product of Sun Nuclear Corporation of Melbourne, Fla. and includes a two dimensional detector array for a quick and precise verification of radiotherapy dose distributions in addition to analysis software designed specifically for radiation dose QA. Details regarding MapCHECK™ may be found at www.sunnuclear.com, the disclosure of which is herein incorporated by reference in its entirety.
With regard to EPID based radiation dose QA of the teachings of the present invention, embodiments of the invention, herein referred to as the EPIDose™, provide a solution to any EPID image to dose for a radiation therapy machine from any manufacturer to dose, such as described in U.S. Pat. Nos. 6,888,919 of Varian Medical Systems, Inc. and 6,810,108 of Siemens Medical Solutions USA, Inc.
As above described, the EPIDose™ process may include a first step using raw EPID input. The EPID is projected to a desired dose plane location and corrected for Output Factor differences between EPID and dose. By way of example, a correction may be made for each and every multileaf collimator (MLC) sub-field to correct for “source distribution” of scattered photons and variations in response off axis and under MLC leaves. Further, the results of step one may be convolved with a “Dose Redistribution Kernel” which converts the dose from EPID point spread function (typically sharper than a dose kernel in tissue or tissue-equivalent media) to a tissue equivalent deposition of dose at a modeled QA depth. Relative comparisons with MapCHECK™ array measurements or a treatment planning system (TPS) may be performed, by way of example. Absolute dose comparisons may be performed after the step including an application of a wide-field calibration that may have been pre-stored in the model using MapCHECK™ calibration files.
EPIDose™ includes Physics Modeling that may be configured and optimized (per Linac, energy, delivery mobility) for a specific EPIDose™ setup. By way of example, after EPIDose™ completing initial physics modeling, it is not required again unless the EPID response drifts, is recalibrated or is serviced. Yet further, EPID image acquisition may be done at convenient and multiple EPID detector distances (typically from 100 cm to 140 cm or 145 cm), at any gantry angle, and without the need for buildup material on the imager.
For a fuller understanding of the invention, reference is made to the following detailed description, taken in connection with the accompanying drawings illustrating various embodiments of the present invention, in which:
The present invention will now be described more fully with reference to the accompanying drawings in which alternate embodiments of the invention are shown and described. It is to be understood that the invention may be embodied in many different forms and should not be construed as limited to the illustrated embodiments set forth herein. Rather, these embodiments are provided so that this disclosure may be thorough and complete, and will convey the scope of the invention to those skilled in the art.
With reference initially to
The system 10 may be further described with reference to
As above described, an output factor correction map 16 is developed specific to the radiation treatment beam 34. As illustrated with reference to
By way of further illustration, reference is made to
With reference to
The process may be further described by way of example with reference to the annotated flow chart of
With continued reference to
Once the output corrected EPID image 20 is obtained as above described by way of example, it is modified by convolution with the redistribution kernel 22, as illustrated with reference to
One computational logic for obtaining the normalized kernel 22 (a Dose Redistribution Function), may be described by way of example to include the steps of finding a shape of the kernel through an iteration to best fit versus known profiles, then normalizing by rastering through the 2-D (e.g. 10 mm×10 mm) radial scatter kernel K(r) and keeping a running sum of the kernel values, and dividing each kernel element by the area kernel sum to provide a normalized kernel (e.g. area sum=1.00). Call this KNORM(r).
Continue by stepping through all EPID pixels to modify the array value (to derive D from C) as follows: For each pixel (i,j), sum (by “collecting”) the scatter dose from surrounding pixels: Do for all C(i,j)>=D threshold, Centered on (i,j), raster through the surrounding 10 mm×10 mm area, and From each surrounding pixel (m,n), “collect” the redistributed dose: Output D(i,j)=KNORM(sqrt[(i−m)2+(j−n)2])*Output C(m,n). Alternatively an FFT convolution may be employed for a faster process than a superposition, specifically by employing a 2-D Fast Fourier Transform (FFT) method.
With reference again to
With reference again to
Yet further, and with continued reference to
By way of further example, and as described above, a correction may be made for each and every multileaf collimator (MLC) sub-field to correct for a source distribution of scattered photons and variations in response off axis and under MLC leaves. Further, the output corrected EPID may then be convolved with a Dose Redistribution Kernel which converts the dose from EPID point spread function (typically sharper than a dose kernel) to a water equivalent deposition of dose at a modeled QA depth. Relative comparisons using MapCHECK™ array measurements or a treatment planning system (TPS) may be performed. The absolute dose comparisons may include an application of the wide-field calibration that may have been pre-stored in the model using MapCHECK™ calibration files.
As above described, the redistribution kernel 22 provides a correction factor for modifying a dose measurement in air to an equivalent dose measurement in water. As will be understood by those of ordinary skill in the art, a treatment plan will typically be established with the result that measurements may account for a modeled QA depth 64 in water using a phantom 66 based on the established preselected dose plane or treatment plane 38 and its source to plane distance 48, as illustrated with reference to
To further illustrate embodiments of the invention through commercially available products, one system 10 may comprise a MapCHECK™ EPIDose™ system for an EPID image file via the format DICOM RT (digital imaging and communications in medicine for radiation therapy) Image, selecting an associated plan file (DICOM RT Plan) to gather the MLC segment data, selecting the appropriate EPIDose model, and then converting to a simulated dose plane. This dose plane, derived from a measured EPID image may then be compared to a dose plane generated by the treatment planning system (TPS). The EPIDose™ process provides the measured dose plane. IMRT QA analysis and a commissioning of the EPIDose™ are illustrated with reference to
By way of further example by assessing the efficacy and quantifying the accuracy of results for embodiments of the present invention, one method is reviewed for IMRT QA in which the measured dose plane is derived from an EPID image, a Si EPID data was acquired and converted using the teachings of the present invention for a method based on a machine-specific beam model to estimate QA dose planes from mega voltage (MV) EPID images. Dose planes were calculated in a homogeneous, water-equivalent QA phantom using the model and an acquired MV EPID image with no additional build-up required on the EPID. Specific parameters, such as field size output dependency, dose redistribution kernel, potential off-axis corrections and absolute dose calibration, were measured to create the model that is based on raw EPID files.
QA dose planes were compared to MapCHECK™ diode array measurements, and also to dose planes calculated by Philips Pinnacle® TPS and the Varian Eclipse TPS. MapCHECK™ measurements and TPS IMRT QA calculations were acquired at a source to detector distance (SDD) of 100 cm at 5 cm water equivalent depth. Corresponding EPIDose dose planes were estimated using EPID images acquired at 140 cm source-to-EPID distance for the attached EPIDose Performance Set 1 and at 105 cm source-to-EPID distance for Sets 2 and 3. Data was collected for both 6 MV (see attached EPIDose Performance Set 1 and Set 2) and 10 MV (see attached Set 3) energies to determine the accuracy of EPIDose for a range of clinical energies. Preliminary analyses demonstrated that the dose planes estimated by the model using EPID images of complex IMRT fields result in >98% pass rate of all point measurements from MapCHECK™, employing a 2% dose or a 2 mm distance to agreement criterion. Setup, acquisition and analysis can be performed in a more time efficient manner than is possible with current methods of IMRT QA for this superior data density.
Many modifications and other embodiments of the invention will come to the mind of one skilled in the art having the benefit of the teachings presented in the foregoing descriptions and the associated drawings. Therefore, it is understood that the invention is not to be limited to the specific embodiments disclosed, and that modifications and embodiments are intended to be included within the scope of the claims supported by this disclosure.
This application claims the benefit of U.S. Provisional Application No. 60/989,586 for “EPID Dosimetry System and Method” having filing date Nov. 21, 2007, the disclosure of which is incorporated herein by reference in its entirety, all being commonly owned.
Number | Name | Date | Kind |
---|---|---|---|
4450440 | White | May 1984 | A |
5394452 | Swerdloff et al. | Feb 1995 | A |
6038283 | Carol et al. | Mar 2000 | A |
6125335 | Simon et al. | Sep 2000 | A |
6175761 | Frandsen et al. | Jan 2001 | B1 |
6345114 | Mackie et al. | Feb 2002 | B1 |
6516046 | Frohlich et al. | Feb 2003 | B1 |
6552347 | Dimcovski | Apr 2003 | B1 |
6626569 | Reinstein et al. | Sep 2003 | B2 |
6636622 | Mackie et al. | Oct 2003 | B2 |
6810107 | Steinberg | Oct 2004 | B2 |
6810108 | Clark et al. | Oct 2004 | B2 |
6839404 | Clark et al. | Jan 2005 | B2 |
6842502 | Jaffray et al. | Jan 2005 | B2 |
6853702 | Renner | Feb 2005 | B2 |
6888919 | Graf | May 2005 | B2 |
6904125 | Van Dyke et al. | Jun 2005 | B2 |
7076023 | Ghelmansarai et al. | Jul 2006 | B2 |
7127030 | Tamegai | Oct 2006 | B2 |
7221733 | Takai et al. | May 2007 | B1 |
7233688 | Ritt et al. | Jun 2007 | B2 |
7298820 | Nelson | Nov 2007 | B2 |
7471765 | Jaffray et al. | Dec 2008 | B2 |
7832928 | Topfer et al. | Nov 2010 | B2 |
20040068182 | Misra | Apr 2004 | A1 |
20060266951 | Fritsch et al. | Nov 2006 | A1 |
20070041497 | Schnarr et al. | Feb 2007 | A1 |
20070071169 | Yeo et al. | Mar 2007 | A1 |
20070081629 | Yin et al. | Apr 2007 | A1 |
20080049896 | Kuduvalli | Feb 2008 | A1 |
20080103834 | Reiner | May 2008 | A1 |
20080107229 | Thomas et al. | May 2008 | A1 |
20100020933 | Topfer et al. | Jan 2010 | A1 |
20110228906 | Jaffray et al. | Sep 2011 | A1 |
Number | Date | Country | |
---|---|---|---|
60989586 | Nov 2007 | US |